New Alzheimer drugs lecanemab and donanemab require monitoring for Amyloid-Related Imaging Abnormalities. These safety issues involve temporary brain swelling or micro-bleeding. Monitoring protocols include frequent MRI scans and genetic screening for the APOE4 gene. Patients must report any persistent headaches or confusion immediately.
- Brain swelling: ARIA-E causes fluid buildup in 13–24% of clinical trial patients.
- Micro-bleeding: ARIA-H affects roughly 17–28% of participants during treatment cycles.
- Infusion reactions: Up to 26% of patients experience fever, chills, or nausea.
- Genetic screening: APOE4 gene testing identifies patients at a higher risk for ARIA.
- Medication review: Use of blood thinners increases the chance of serious bleeding.
Bookimed Expert Insight: Ukraine remains a major hub for neurodegenerative care with centers like Impuls Medical Center treating 6,000 patients annually. While newer monoclonal antibodies face local availability hurdles, specialists like Dr. Lozovoy Yuri Vladimirovich offer alternative neuro-rehabilitation with 20+ years of expertise. Patients often choose Kyiv clinics for cellular therapies where ISO-certified facilities like Good Cells Clinic ensure rigorous quality standards.
Patient Consensus: Patients emphasize the need for monthly MRIs during the first 6 months to catch silent brain bleeds. Many note that skipping genetic tests or scans to save costs is dangerous, especially for those with the APOE4 gene.